S-1: Capstone Holding Registers 4.3M Shares for Resale

Sentiment:

Registration Statement


Capstone Holding Corp. filed an S-1 registration statement for the resale of 4,306,664 shares of common stock by a selling stockholder, 3i, LP, following a convertible note conversion.

Capital raiseThe company issued Senior Secured Convertible Notes to 3i, LP, with an aggregate original principal amount of up to $10,909,885, including an 8.34% original issue discount.The first Convertible Note was issued for approximately $3,272,966, and the second for approximately $3,545,712.42.The company received gross proceeds of $3,250,000 from the initial closing of the Convertible Note Financing.The company may receive up to an additional $3,750,000 in gross proceeds from further issuances of Convertible Notes (aggregate principal amount of $4,091,207) pursuant to the Purchase Agreement.On September 30, 2025, the company exchanged approximately $1.94 million in notes from Brookstone entities for newly created Series Z 8% Non-Convertible Preferred Stock.On March 7, 2025, the company closed a follow-on public offering of 1,250,000 shares of Common Stock.

Summary

  • Capstone Holding Corp. is registering 4,306,664 shares of common stock for resale by 3i, LP, which are issuable upon conversion of a convertible note with a principal amount of $3,545,712.42 at a fixed conversion price of $1.10 per share.
  • The company will not receive any proceeds from this specific resale by the selling stockholder.
  • Capstone operates as a building products distribution network, primarily through its subsidiary Instone, a leading distributor of thin veneer stone and related masonry products in the U.S.
  • The company is controlled by Brookstone Partners, a private equity group, through entities owned by CEO Matthew Lipman and Chairman Michael Toporek, who collectively own over 50% of the common and voting stock.
  • Recent developments include the acquisition of Carolina Stone Holdings for $2,625,000 in cash, a $1,250,000 seller note, and an earn-out, which closed on August 22, 2025.
  • On September 30, 2025, Brookstone entities exchanged approximately $1.94 million in notes for 1,467,343 shares of the newly created Series Z 8% Non-Convertible Preferred Stock, valued at $1.32 per share.

Sentiment

Score: 7

Explanation: Capstone Holding Corp. demonstrates a clear growth strategy through acquisitions and product innovation, supported by experienced leadership and recent uplisting to Nasdaq. The acquisition of Carolina Stone Holdings and the introduction of the Toro product line are positive indicators. However, the significant dilution from the selling stockholder's resale, the existing net tangible book deficit, and the ongoing need for additional financing present notable risks.

Positives

  • Instone's revenues increased from approximately $32.2 million in April 2020 to approximately $44.9 million by December 31, 2024, demonstrating organic growth.
  • Successfully acquired Carolina Stone Holdings on August 22, 2025, expanding its market presence and product offerings.
  • Possesses a strong leadership team with deep industry expertise, including executives from Brookstone Partners and former Owens Corning Group President Charles Dana.
  • Strategically positioned to capitalize on M&A opportunities in the building products sector, aligning with industry trends for increased shareholder returns from frequent acquisitions.
  • Has a proven track record of successfully integrating four acquisitions since 2006.
  • Expanded its geographic distribution footprint, onboarding customers in 6 new states in 2024, now servicing 31 states.
  • Introduced the 'Toro' family of manufactured stone products, which is expected to drive significant organic revenue growth in the next three years.
  • Uplisted its Common Stock to the Nasdaq Capital Market under the symbol CAPS on March 6, 2025, enhancing market visibility and liquidity.

Negatives

  • The resale of 4,306,664 shares by the selling stockholder will cause dilution to existing stockholders.
  • The company will not receive any proceeds from the resale of shares by the selling stockholder.
  • Investing in the company's securities involves a high degree of risk, as explicitly stated in the filing.
  • There is potential for future dilution from additional equity or convertible debt financings.
  • Management has broad discretion over the use of proceeds from the company's sale of Convertible Notes, which may not align with all stockholder interests.
  • The selling stockholder may sell shares at prices below the current market price, which could adversely affect the market price of the company's Common Stock.
  • Reported a net tangible book value (deficit) of $(7,435,772) or $(1.38) per share as of June 30, 2025, indicating a negative equity position.
  • New investors face an immediate dilution of $1.52 per share based on the as-adjusted net tangible book value after the offering.

Risks

  • The issuance of Common Stock to the selling stockholder may cause dilution and the sale of such shares, or the perception of such sales, could cause the price of Common Stock to decrease.
  • The company is not restricted from issuing additional securities in the future, including common stock or convertible debt, which would result in further dilution to stockholders.
  • The company may require additional financing to sustain operations, and if unavailable or prohibitively dilutive, it may not be able to continue operations.
  • Management will have broad discretion as to the use of proceeds from the company's sale of Convertible Notes, and such uses may not improve financial condition or market value.
  • The selling stockholder may choose to sell the shares at prices below the current market price, adversely affecting the market price of Common Stock.
  • Future equity offerings and other issuances of Common Stock or other securities may adversely affect the Common Stock price and could result in investors purchasing shares with rights superior to existing stockholders.
  • Dilution will be incurred upon the exercise of any outstanding stock options, warrants, or upon the issuance of shares under stock incentive programs.
  • Operating in a very competitive and rapidly changing environment, with new risks emerging that are difficult to predict.
  • Forward-looking statements involve risks and uncertainties which could cause actual results to differ materially from those contemplated.

Future Outlook

Capstone Holding Corp.'s long-term growth strategy is built on expanding its building products distribution and manufacturing business through both organic growth and strategic acquisitions. The company intends to increase its geographic footprint, enhance its product portfolio (e.g., with the new Toro manufactured stone products expected to drive significant organic revenue growth in the next three years), and optimize operations for efficiency. Management anticipates benefiting from valuation premiums as the company scales its EBITDA and maintains consistent earnings performance. Proceeds from future Convertible Note issuances are intended for acquisition costs, fees, and general corporate purposes, including working capital. The company acknowledges the need for additional financing to sustain operations.

Management Comments

  • "We believe we are strategically positioned to capitalize on market conditions within the building products sector."
  • "Historically, acquiring companies at interest rate peaks has yielded strong returns, and we are poised to leverage these strategic investment opportunities as the market evolves."
  • "Our customers are at the heart of everything we do. We are committed to building strong, long-lasting relationships by providing high-quality products, exceptional service, and expert support."
  • "Our goal is to be the preferred partner for our customers, helping them succeed in their projects and achieve their business objectives."
  • "We expect Toro to help drive significant organic revenue growth in the next three years."
  • "As Capstone continues to scale, growing its EBITDA, we anticipate benefiting from valuation premiums associated with increased size. This growth, coupled with consistent earnings performance, is expected to drive substantial shareholder value and enhance our market positioning."

Industry Context

The company's strategy aligns with broader industry trends in the building products sector, which, according to the Bain & Company Global M&A Report (2024), offers significant M&A opportunities. The report highlights that companies making frequent and material acquisitions substantially outperform inactive companies in total shareholder returns (9.6% vs 2.7%). The current market environment is seen as favorable for acquisitions due to 'ample one-off opportunities to acquire struggling assets' and reduced competition from financial investors. Capstone's focus on both 'scale M&A' for operational synergies and 'scope M&A' to build product, geography, and capability adjacencies directly reflects these industry dynamics.

Comparison to Industry Standards

  • Capstone's strategy of pursuing frequent and material acquisitions, as evidenced by its successful integration of four acquisitions since 2006 and the recent Carolina Stone Holdings acquisition, aligns with the Bain & Company Global M&A Report's finding that such companies substantially outpace inactive companies in total shareholder returns (9.6% vs 2.7%).
  • The company's expansion into 6 new states in 2024 and its focus on broadening its product portfolio, including the new Toro manufactured stone products, reflects the industry trend of pursuing 'scope M&A' to build product, geography, and capability adjacencies, as recommended by the Bain Report.
  • Capstone's leadership team, including Charles Dana (former Group President Building Materials at Owens Corning), brings deep industry expertise comparable to that found in leading building materials companies, providing a strong foundation for evaluating and integrating acquisitions.

Corporate Governance

Change TypeDescriptionEffective DateImpact Assessment
Controlled Company StatusIdentified as a controlled company under Nasdaq Stock Market Rules due to entities controlled by Matthew Lipman (CEO) and Michael Toporek (Chairman) owning over 50% of common and voting stock. However, the company does not intend to rely on the associated corporate governance exemptions.As of October 23, 2025Maintains higher corporate governance standards than required for a controlled company, potentially enhancing investor confidence.
Emerging Growth & Smaller Reporting Company StatusQualifies as an emerging growth company and a smaller reporting company, allowing for scaled disclosure. The company has elected not to use the extended transition period for complying with new or revised financial accounting standards.OngoingProvides reduced disclosure in certain areas but adheres to public company accounting standards, offering a balance of regulatory relief and financial transparency.
Director and Officer IndemnificationThe restated certificate of incorporation and bylaws provide for indemnification of officers and directors to the fullest extent permitted by Delaware General Corporation Law, and eliminates personal liability of directors for monetary damages for breaches of fiduciary duties with specific exceptions.OngoingProtects directors and officers from certain liabilities, which can aid in attracting and retaining qualified personnel, but also limits recourse for shareholders in some cases.

Related Party Transactions

  • Brookstone Partners, controlled by CEO Matthew Lipman and Chairman Michael Toporek, is a significant related party.
  • On September 30, 2025, Brookstone entities (BP Peptides, LLC and Brookstone Partners Acquisition XXI Corporation) exchanged notes with an aggregate principal and interest amount of approximately $1.94 million for 1,467,343 shares of the newly created Series Z 8% Non-Convertible Preferred Stock.
  • On July 14, 2017, BP Peptides, LLC (Brookstone) funded $3,440,000 to the company, including $1,012,500 for common stock and $2,427,500 as a secured loan.
  • In December 2020, Brookstone converted $572,700 of accrued interest and secured debt into 24,900 shares of Common Stock.
  • In March 2022, Brookstone converted $688,104 of accrued interest and $1,951,260 of secured debt into 78,153 shares of Common Stock, increasing its ownership to 77.3%.
  • In November 2023, Capstone and Brookstone Acquisition Partners XXI, LLC (a related entity) agreed to terms of an unsecured promissory note for $800,000, formalized on March 31, 2024, which replaced an $8 million secured note.
  • On November 11, 2024, BP Peptides, LLC (a Brookstone entity) and the company agreed to the Second Amended and Restated Note for $700,617.52 principal and $101,810.28 accrued interest, extending its maturity to June 30, 2026.
  • On February 25, 2025, Nectarine Management LLC, an entity controlled by Michael Toporek, purchased 985,063 shares of Series B Preferred Stock for $30,000.

Stakeholder Impact

  • **Shareholders**: Will experience dilution from the resale of 4,306,664 shares by 3i, LP, and face potential future dilution from additional equity offerings. The market price of common stock could be negatively impacted by sales by the selling stockholder. Existing stockholders will see an immediate increase in net tangible book value of $0.61 per share, while new investors face a dilution of $1.52 per share.
  • **Customers**: The company's strategy emphasizes a customer-centric approach, expanding its product portfolio, and improving service, aiming to enhance customer satisfaction and be a preferred partner.
  • **Creditors**: The issuance of Senior Secured Convertible Notes and the existing revolving credit facility with Berkshire Bank indicate ongoing financing arrangements. The notes exchange with Brookstone entities converted debt into preferred stock, altering the capital structure.
  • **Company**: Will not receive proceeds from the resale, but the Convertible Note Financing provides capital for acquisitions and general corporate purposes. The company's growth strategy aims to increase EBITDA and shareholder value.

Next Steps

  • The selling stockholder (3i, LP) may offer and sell or otherwise dispose of the 4,306,664 shares of Common Stock from time to time.
  • The company may issue further Convertible Notes in the aggregate principal amount of $4,091,207 to the selling stockholder, potentially receiving an additional $3,750,000 in gross proceeds.
  • The company intends to expand its geographic footprint, increase market penetration, and enter new, underserved regions through organic growth and strategic acquisitions.
  • The company plans to continuously expand and diversify its product offerings, including new textures, colors, and materials within its stone product lines, and into adjacent building products.
  • The company is focused on optimizing its operations to improve efficiency, reduce costs, and enhance customer satisfaction through investments in advanced technologies and supply chain streamlining.
  • The company expects the Toro family of manufactured stone products to drive significant organic revenue growth in the next three years.
  • The company will continue to comply with SEC reporting requirements as an emerging growth and smaller reporting company.

Key Dates

DateDescription
1987Company formed as OrthoLogic Corp.
2005Company filed its restated certificate of incorporation.
October 4, 2006TotalStone, LLC formed.
February 2008Brookstone Partners affiliate invested $8.8 million in Woodcrafters Home Products Holdings LLC.
2010Company changed its name to Capstone Therapeutics Corp.
December 2013Brookstone completed the sale of all its interests in Woodcrafters for $32 million.
June 22, 2015Amended and Restated Certificate of Designation of Series A Preferred Stock.
December 11, 2015Convertible promissory notes issued (paid off July 14, 2017).
August 25, 2016Series B Preferred Stock and Warrant Purchase Agreement.
July 14, 2017Company entered into Securities Purchase, Loan and Security Agreement with BP Peptides, LLC (Brookstone), funding $3,440,000.
July 14, 2017Brookstone purchased 6,722 shares of Common Stock directly from Biotechnology Value Fund affiliated entities.
August 11, 2017Series B-2 Preferred Stock Purchase Agreement.
December 20, 2017Revolving Credit, Term Loan and Security Agreement with Berkshire Bank.
January 30, 2018First Amendment to Securities Purchase Loan and Security Agreement.
January 30, 2018Warrant to Purchase Common Stock issued to BP Peptides, LLC.
March 15, 2019Second Amendment to Securities Purchase Loan and Security Agreement.
August 22, 2019Company filed a certificate of amendment for a 1 for 1,000 reverse stock split.
August 23, 2019LipimetiX Development, Inc. Contingent Value Rights Agreement.
November 14, 2019NEM Purchaser, LLC completed the purchase of Northeast Masonry Distributors, LLC for $6,029,342.
March 1, 2020Brookstone Partners IAC, Inc. Amended and Restated Management Fee Agreement.
March 2020Company and Brookstone amended the Brookstone Agreement to extend Secured Debt maturity to March 31, 2022.
March 27, 2020Third Amendment to Securities Purchase Loan and Security Agreement.
March 27, 2020Management Fee Agreement between TotalStone, LLC and Capstone Holding Corp.
April 1, 2020Company acquired a controlling interest in TotalStone.
December 2020Brookstone converted $572,700 of accrued interest and secured debt into 24,900 shares of Common Stock at $23 per share.
February 10, 2021Company filed a certificate of amendment decreasing authorized Common Stock to 200,000 shares and preferred stock to 5,000 shares.
March 15, 2021Fourth Amendment to Securities Purchase Loan and Security Agreement.
March 31, 2021Limited Payment Guarantee between Capstone Therapeutics Corp. and Brookstone Acquisition Partners XXI Corporation.
November 22, 2021Term Note Issued by TotalStone, LLC, Northeast Masonry Distributors, LLC, and TotalStone Properties, LLC to Berkshire Bank.
February 18, 2022Company legally changed its name from Capstone Therapeutics Corp. to Capstone Holding Corp.
March 2022Brookstone converted $688,104 of accrued interest and $1,951,260 of secured debt into 78,153 shares of Common Stock at $24.75 per share.
March 8, 2023Second Amended and Restated Credit Agreement with Stream Finance, LLC.
November 2023Capstone and Brookstone Acquisition Partners XXI, LLC agreed to terms of an unsecured promissory note for $800,000.
March 31, 2024Formalized the $800,000 unsecured promissory note.
May 1, 2024Board authorized and declared a dividend distribution of one right for each outstanding share of Common Stock (Tax Benefit Preservation Plan).
November 11, 2024BP Peptides, LLC and the Company agreed to the Second Amended and Restated Note for $700,617.52 principal and $101,810.28 accrued interest, extending maturity to June 30, 2026.
November 11, 2024Second Amended and Restated Promissory Note issued by Capstone Holding Corp. to Brookstone Partners Acquisition XXI Corporation.
November 15, 2024Amendment of Amended and Restated Management Fee and Transaction Fee Agreement.
December 31, 2024Instone's revenues increased to approximately $44.9 million.
February 14, 2025Registration statement on Form 8-A12B filed.
February 20, 2025Company filed an amendment to its Restated Certificate of Incorporation to increase authorized shares of Common Stock to 50,000,000 and preferred stock to 25,000,000.
February 20, 2025Company filed a Certificate of Designation for Series B Preferred Stock (2 million shares authorized).
February 25, 2025Company entered into a subscription agreement with Nectarine Management LLC for the sale and issuance of 985,063 shares of Series B Preferred Stock for $30,000.
March 3, 2025The Tax Benefit Preservation Plan was cancelled.
March 6, 2025Company's Common Stock began trading on the Nasdaq Capital Market under the symbol CAPS.
March 6, 2025985,063 shares of Series B Preferred Stock issued to Nectarine Management LLC.
March 7, 2025Company closed its follow-on public offering of 1,250,000 shares of Common Stock.
March 7, 2025Restructuring completed, making the Company the sole member of TotalStone.
March 11, 2025Current Report on Form 8-K filed.
March 31, 2025Annual Report on Form 10-K for the year ended December 31, 2024 filed.
April 1, 2025Management agreement between TotalStone and the Company terminated.
April 1, 2025Current Report on Form 8-K filed.
May 14, 2025Common Stock Purchase Agreement and Registration Rights Agreement entered into with Tumim Stone Capital, LLC.
May 15, 2025Quarterly Report on Form 10-Q for the period ended March 31, 2025 filed.
June 27, 2025Current Report on Form 8-K filed.
June 30, 2025Net tangible book value (deficit) of $(7,435,772) or $(1.38) per share.
June 30, 2025Current Report on Form 8-K filed.
July 26, 2025Stockholder approval obtained to issue shares in excess of Nasdaq's 19.99% Exchange Cap.
July 29, 2025Company entered into the Purchase Agreement with 3i, LP for Senior Secured Convertible Notes.
July 29, 2025First Convertible Note issued in the principal amount of approximately $3,272,966.
July 29, 2025Second Convertible Note issued in the principal amount of approximately $3,545,712.42.
July 29, 2025Company entered into a Registration Rights Agreement and a Security Agreement with 3i, LP.
August 4, 2025Current Report on Form 8-K filed.
August 11, 2025Registration statement on Form S-1, File No. 333-289222, declared effective for the first Convertible Note.
August 15, 2025Company entered into a membership interest purchase agreement to acquire Carolina Stone Holdings, LLC.
August 15, 2025Quarterly Report on Form 10-Q for the period ended June 30, 2025 filed.
August 18, 2025Current Report on Form 8-K filed.
August 22, 2025Acquisition of Carolina Stone Holdings closed.
September 30, 2025Company entered into an exchange agreement with Brookstone entities for notes totaling approximately $1.94 million for Series Z 8% Non-Convertible Preferred Stock.
September 30, 2025Company filed the Certificate of Designation for Series Z 8% Non-Convertible Preferred Stock.
October 6, 2025Current Report on Form 8-K filed.
October 20, 2025Nasdaq Capital Market average high/low price used for fee calculation.
October 22, 2025Closing sale price of Common Stock was $1.14 per share.
October 22, 2025Senior Secured Convertible Note issued by Capstone Holding Corp. to 3i, LP.
October 23, 2025Filing date of this S-1 Registration Statement.
April 1, 2027Final expiration date of the Tax Benefit Preservation Plan (though the plan was cancelled on March 3, 2025).

Recommendation

hold

Capstone Holding Corp. is executing a clear growth strategy in the building products sector, marked by recent acquisitions, product innovation (Toro), and an uplisting to Nasdaq. The company has an experienced leadership team and a track record of successful integrations. However, the immediate dilution from the selling stockholder's resale of 4.3 million shares, the existing net tangible book deficit, and the ongoing need for additional financing introduce significant uncertainty and potential downward pressure on the stock price. While the long-term strategy appears sound, the near-term dilutive events and financial position warrant a cautious approach. Investors should monitor the impact of the share resale and the company's ability to effectively deploy capital from future Convertible Note issuances to achieve its growth objectives before considering further investment.

Keywords

Capstone Holding Corp, CAPS, S-1, SEC filing, registration statement, common stock, resale, convertible note, 3i LP, building products, Instone, thin veneer stone, masonry products, distribution network, acquisition, Carolina Stone Holdings, Series Z Preferred Stock, Brookstone Partners, dilution, Nasdaq, emerging growth company, smaller reporting company, financial reporting, risk factors

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.